Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Syndecan-1 | 8 | 2012 | 20 | 2.050 |
Why?
|
| Prostatic Neoplasms | 10 | 2013 | 489 | 1.610 |
Why?
|
| Fatty Acids, Omega-3 | 10 | 2013 | 69 | 1.560 |
Why?
|
| Docosahexaenoic Acids | 4 | 2012 | 25 | 1.400 |
Why?
|
| Apoptosis | 8 | 2013 | 367 | 1.300 |
Why?
|
| Proteoglycans | 5 | 2012 | 34 | 1.110 |
Why?
|
| Breast Neoplasms | 5 | 2013 | 767 | 0.790 |
Why?
|
| Arachidonate 15-Lipoxygenase | 2 | 2012 | 3 | 0.750 |
Why?
|
| Signal Transduction | 9 | 2013 | 716 | 0.660 |
Why?
|
| Mammary Glands, Animal | 2 | 2011 | 69 | 0.660 |
Why?
|
| Cell Proliferation | 6 | 2013 | 599 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2013 | 74 | 0.510 |
Why?
|
| PPAR gamma | 5 | 2012 | 51 | 0.500 |
Why?
|
| Lipoproteins, LDL | 3 | 2005 | 83 | 0.450 |
Why?
|
| Cell Line, Tumor | 8 | 2013 | 726 | 0.430 |
Why?
|
| bcl-Associated Death Protein | 3 | 2011 | 11 | 0.430 |
Why?
|
| Heparan Sulfate Proteoglycans | 2 | 2004 | 4 | 0.420 |
Why?
|
| Animals | 18 | 2013 | 8165 | 0.390 |
Why?
|
| Glucose | 2 | 2004 | 158 | 0.390 |
Why?
|
| Fatty Acids | 2 | 2013 | 100 | 0.390 |
Why?
|
| Endothelial Cells | 2 | 2004 | 190 | 0.370 |
Why?
|
| Fatty Acid Desaturases | 2 | 2011 | 51 | 0.350 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2009 | 38 | 0.350 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2011 | 11 | 0.340 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 32 | 0.340 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2011 | 11 | 0.340 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2010 | 49 | 0.320 |
Why?
|
| Receptors, Androgen | 2 | 2011 | 44 | 0.310 |
Why?
|
| Blotting, Western | 4 | 2011 | 297 | 0.310 |
Why?
|
| Mice | 8 | 2013 | 2544 | 0.300 |
Why?
|
| Epidermal Growth Factor | 1 | 2009 | 25 | 0.300 |
Why?
|
| Fatty Acids, Unsaturated | 4 | 2013 | 43 | 0.290 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2013 | 26 | 0.290 |
Why?
|
| Liver | 1 | 2011 | 491 | 0.280 |
Why?
|
| Prostate | 1 | 2008 | 88 | 0.260 |
Why?
|
| Humans | 20 | 2013 | 32284 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 257 | 0.250 |
Why?
|
| Phosphorylation | 4 | 2011 | 248 | 0.250 |
Why?
|
| Mice, Knockout | 4 | 2011 | 441 | 0.240 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 478 | 0.230 |
Why?
|
| Mice, Transgenic | 5 | 2013 | 254 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 3 | 2011 | 165 | 0.220 |
Why?
|
| Albumins | 1 | 2004 | 42 | 0.220 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 112 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 246 | 0.210 |
Why?
|
| Male | 12 | 2013 | 19434 | 0.200 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 105 | 0.200 |
Why?
|
| Monocytes | 1 | 2004 | 118 | 0.190 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 153 | 0.190 |
Why?
|
| Cattle | 3 | 2010 | 118 | 0.180 |
Why?
|
| RNA, Messenger | 3 | 2010 | 499 | 0.180 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 255 | 0.180 |
Why?
|
| Blood Glucose | 1 | 2002 | 484 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 544 | 0.140 |
Why?
|
| Triglycerides | 2 | 2011 | 234 | 0.130 |
Why?
|
| Cholesterol | 2 | 2011 | 258 | 0.120 |
Why?
|
| Fish Oils | 2 | 2008 | 38 | 0.120 |
Why?
|
| Neoplasms | 3 | 2008 | 763 | 0.120 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2011 | 28 | 0.110 |
Why?
|
| Sulfates | 2 | 2004 | 4 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 1436 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 3 | 2011 | 36 | 0.100 |
Why?
|
| Female | 5 | 2011 | 19954 | 0.100 |
Why?
|
| Aorta | 2 | 2004 | 120 | 0.100 |
Why?
|
| Caspases | 1 | 2012 | 39 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 222 | 0.090 |
Why?
|
| Cell Survival | 1 | 2012 | 286 | 0.090 |
Why?
|
| Cadherins | 1 | 2011 | 28 | 0.090 |
Why?
|
| Cell Movement | 1 | 2012 | 165 | 0.080 |
Why?
|
| Phospholipids | 1 | 2011 | 32 | 0.080 |
Why?
|
| Survival Rate | 2 | 2010 | 892 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 7 | 0.080 |
Why?
|
| Serum Albumin, Bovine | 1 | 2010 | 11 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 47 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 110 | 0.080 |
Why?
|
| Receptor Cross-Talk | 1 | 2009 | 3 | 0.080 |
Why?
|
| Protein Transport | 1 | 2009 | 80 | 0.070 |
Why?
|
| RNA Interference | 1 | 2009 | 77 | 0.070 |
Why?
|
| Linoleic Acid | 2 | 2008 | 19 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2009 | 111 | 0.070 |
Why?
|
| Chromans | 1 | 2008 | 5 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 18 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 64 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 46 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 189 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 203 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2007 | 98 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2011 | 821 | 0.060 |
Why?
|
| Syndecans | 1 | 2005 | 1 | 0.060 |
Why?
|
| Phosphatidylethanolamines | 1 | 2004 | 8 | 0.050 |
Why?
|
| Middle Aged | 2 | 2013 | 11843 | 0.050 |
Why?
|
| Phosphatidylcholines | 1 | 2004 | 29 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 160 | 0.050 |
Why?
|
| Aggrecans | 1 | 2004 | 4 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2004 | 14 | 0.050 |
Why?
|
| Glycosaminoglycans | 1 | 2004 | 23 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 821 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2004 | 95 | 0.050 |
Why?
|
| Gene Expression | 1 | 2005 | 345 | 0.050 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 90 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 325 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 595 | 0.050 |
Why?
|
| Glipizide | 1 | 2002 | 3 | 0.050 |
Why?
|
| Fructosamine | 1 | 2002 | 12 | 0.050 |
Why?
|
| Metformin | 1 | 2002 | 25 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2002 | 470 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 75 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 186 | 0.040 |
Why?
|
| Lipids | 1 | 2002 | 250 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 390 | 0.040 |
Why?
|
| Oxidation-Reduction | 2 | 2011 | 255 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2011 | 14 | 0.020 |
Why?
|
| Receptors, Prostaglandin | 1 | 2011 | 5 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 16 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 22 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2011 | 31 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 78 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 104 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 106 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 285 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 137 | 0.020 |
Why?
|
| Adult | 1 | 2002 | 9263 | 0.020 |
Why?
|
| Aged | 1 | 2002 | 10257 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 500 | 0.020 |
Why?
|
| alpha-Linolenic Acid | 1 | 2008 | 12 | 0.020 |
Why?
|
| Nutritional Support | 1 | 2008 | 5 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2008 | 28 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2008 | 33 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2008 | 39 | 0.020 |
Why?
|
| Protein Prenylation | 1 | 2007 | 3 | 0.020 |
Why?
|
| Racemases and Epimerases | 1 | 2007 | 5 | 0.020 |
Why?
|
| Phytanic Acid | 1 | 2007 | 5 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2007 | 10 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2007 | 40 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 66 | 0.020 |
Why?
|
| Vitamin D | 1 | 2007 | 186 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 312 | 0.010 |
Why?
|
| Models, Animal | 1 | 2006 | 189 | 0.010 |
Why?
|
| Risk | 1 | 2006 | 305 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 590 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2006 | 187 | 0.010 |
Why?
|